In this issue of JAMA Internal Medicine, Steinman and colleagues1 report on their carefully designed observational study of the comparative benefits and harms of β-blocker use for acute myocardial infarction (AMI) in adults 85 years or older—a population for whom no evidence from randomized clinical trials exists. They found that, within 3 months of hospital discharge after AMI, 12.1% of their study population experienced functional decline, 25.3% were rehospitalized, and 14.1% died. Use of β-blockers decreased the odds of death regardless of functional status. This should be good news. Guideline-based medications for AMI have been underused in older adults. The study’s confirmation of the survival benefit for frail elders will likely spur an increase in β-blocker prescribing for older adults with multiple comorbidities.
Tjia J, Lapane K. Guideline-Based Prescribing in Frail Elderly Patients. JAMA Intern Med. 2017;177(2):262–263. doi:10.1001/jamainternmed.2016.7714
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: